Clinical Trial Update: Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating erdafitinib (JNJ-42756493) in patients with advanced hepatocellular carcinoma has completed, assessing safety, pharmacokinetics, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Erdafitinib (erdafitinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: COMPLETED